No Data
Joincare Pharmaceutical Group Industry Obtains Clinical Trial Approval for COPD Treatment
Joincare Pharmaceutical Group Industry (600380.SH): The JKN2403 tablet has received a clinical trial approval notice.
On December 19, Gelonghui reported that Joincare Pharmaceutical Group Industry (600380.SH) announced the receipt of the "Notice of Approval for Clinical Drug Trials" issued by the National Medical Products Administration, approving the company's JKN2403 tablets (referred to as: JKN2403) to conduct clinical trials. JKN2403 tablets are an innovative oral medication independently developed by the company after being introduced from overseas (Europe Phase I clinical successfully). It effectively inhibits the activity of prolyl endopeptidase (PREP), which effectively prevents the production of inflammatory mediators related to chronic obstructive pulmonary disease (COPD), thus controlling acute episodes of COPD.
Investors in Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Have Seen Returns of 21% Over the Past Five Years
Joincare Pharmaceutical Group Industry (600380.SH): has repurchased 1.12% of the shares.
Joincare Pharmaceutical Group Industry (600380.SH) announced on December 2 that in November 2024, the company has repurchased a total of 9,945,896 shares through centralized auction trading, accounting for 0.53% of the total share capital (1,874,200,420 shares). The highest purchase price was 11.90 yuan/share, the lowest price was 11.01 yuan/share, and the total amount paid was 114.1241 million yuan (including transaction fees). As of the end of November 2024, the company had repurchased a total of 20,908,447 shares, accounting for company total share capital (1,874,200,
joincare pharmaceutical group industry (600380.SH): Cumulative repurchase of 0.58% shares
Gelonghui News on November 1: Joincare Pharmaceutical Group Industry (600380.SH) announced that, as of October 31, 2024, the company has repurchased a total of 10,962,551 shares through block trading, accounting for 0.58% of the total share capital of the company (1,874,200,420 shares). The highest repurchase price was 11.41 yuan per share, the lowest price was 10.71 yuan per share, and the total amount paid was 121.2584 million yuan (including fees).
We Like The Quality Of Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Earnings
Are Strong Financial Prospects The Force That Is Driving The Momentum In Joincare Pharmaceutical Group Industry Co.,Ltd.'s SHSE:600380) Stock?
No Data
